Better EFS Outcomes with Perioperative Durvalumab Plus FLOT Than with Placebo Plus FLOT for Resectable Gastric or GEJ Adenocarcinoma By Ogkologos - June 10, 2025 748 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the MATTERHORN study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR Results of Continuous vs Intermittent Dosing Schedules of BRAF/MEK Inhibitor Combination... October 30, 2020 Pirtobrutinib Shows Efficacy in Patients with Heavily Pretreated CLL or SLL... July 18, 2023 Treatment Guided by Comprehensive Genomic Profiling and Expert MTB Decision-Making Improves... October 14, 2025 Breast Cancer Patient Is Accused of Having “Body Image Issues” After... March 5, 2021 Load more HOT NEWS EMA Recommends Granting a Marketing Authorisation for Celdoxome Pegylated Liposomal Workout Wednesday – Back Stretches Part 2 Curbing Production of Immune Checkpoint Protein Slows Liver Cancer in Mice Adjuvant Everolimus Does Not Improve Recurrence-Free Survival Among Patients with Renal...
